Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells - Role of oxidant-induced iron signaling in apoptosis

被引:195
作者
Kotamraju, S
Chitambar, CR
Kalivendi, SV
Joseph, J
Kalyanaraman, B
机构
[1] Med Coll Wisconsin, Biophys Res Inst, Milwaukee, WI 53226 USA
[2] Med Coll Wisconsin, Free Radical Res Ctr, Milwaukee, WI 53226 USA
[3] Med Coll Wisconsin, Div Neoplast Dis, Milwaukee, WI 53226 USA
关键词
D O I
10.1074/jbc.M111604200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In the past, investigators have successfully used iron chelators to mitigate the cardiotoxicity of doxorubicin (DOX), a widely used anticancer drug that induces reactive oxygen species (ROS), oxidative damage, and apoptosis. Although intracellular iron plays a critical role in initiating DOX-induced apoptosis, the molecular mechanism(s) that link iron, ROS, and apoptosis are still unknown. In this study, we demonstrate that apoptosis results from the exposure of bovine aortic endothelial cells to DOX and that the apoptotic cell death is accompanied by a significant increase in cellular iron (Fe-55) uptake and activation of iron regulatory protein-1. Furthermore, DOX-induced iron uptake was shown to be mediated by the transferrin receptor (TfR)-dependent mechanism. Treatment with the anti-TfR antibody (IgA class) dramatically inhibited DOX-induced apoptosis, iron uptake, and intracellular oxidant formation as measured by fluorescence using dichlorodihydrofluorescein. Treatment with cell-permeable iron chelators and ROS scavengers inhibited DOX-induced cellular Fe-55 uptake, ROS formation, and apoptosis. Based on these findings, we conclude that DOX-induced iron signaling is regulated by the cell surface TfR expression, intracellular oxidant levels, and iron regulatory proteins. The implications of TfR-dependent iron transport in oxidant-induced apoptosis in endothelial cells are discussed.
引用
收藏
页码:17179 / 17187
页数:9
相关论文
共 72 条
[1]   Hydrogen peroxide mediates the cell growth and transformation caused by the mitogenic oxidase Nox1 [J].
Arnold, RS ;
Shi, J ;
Murad, E ;
Whalen, AM ;
Sun, CQ ;
Polavarapu, R ;
Parthasarathy, S ;
Petros, JA ;
Lambeth, JD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (10) :5550-5555
[2]  
BACHUR NR, 1977, MOL PHARMACOL, V13, P901
[3]  
BALLA G, 1992, J BIOL CHEM, V267, P18148
[4]   Critical evaluation of the use of hydroethidine as a measure of superoxide anion radical [J].
Benov, L ;
Sztejnberg, L ;
Fridovich, I .
FREE RADICAL BIOLOGY AND MEDICINE, 1998, 25 (07) :826-831
[5]   HBED: The continuing development of a potential alternative to deferoxamine for iron-chelating therapy [J].
Bergeron, RJ ;
Wiegand, J ;
Brittenham, GM .
BLOOD, 1999, 93 (01) :370-375
[6]   ADRIAMYCIN - NEW ANTICANCER DRUG WITH SIGNIFICANT CLINICAL ACTIVITY [J].
BLUM, RH ;
CARTER, SK .
ANNALS OF INTERNAL MEDICINE, 1974, 80 (02) :249-259
[7]  
BRISTOW MR, 1978, CANCER TREAT REP, V62, P873
[8]   Cytochrome c is a potent catalyst of dichlorofluorescin oxidation:: Implications for the role of reactive oxygen species in apoptosis [J].
Burkitt, MJ ;
Wardman, P .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 282 (01) :329-333
[9]   EFFECTS OF DIFFERENT TRANSFERRIN FORMS ON TRANSFERRIN RECEPTOR EXPRESSION, IRON UPTAKE, AND CELLULAR PROLIFERATION OF HUMAN-LEUKEMIC HL60 CELLS - MECHANISMS RESPONSIBLE FOR THE SPECIFIC CYTOTOXICITY OF TRANSFERRIN-GALLIUM [J].
CHITAMBAR, CR ;
SELIGMAN, PA .
JOURNAL OF CLINICAL INVESTIGATION, 1986, 78 (06) :1538-1546
[10]   TOXICITY PROFILE OF DEXRAZOXANE (ZINECARDR, ICRF-187, ADR-529, NSC-169780), A MODULATOR OF DOXORUBICIN CARDIOTOXICITY [J].
CURRAN, CF ;
NARANG, PK ;
REYNOLDS, RD .
CANCER TREATMENT REVIEWS, 1991, 18 (04) :241-252